Last update 26 Jun 2025

Tildrakizumab-ASMN

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Ilumetri, ILUMYA, tildrakizumab
+ [21]
Target
Action
inhibitors
Mechanism
IL-23p19 inhibitors(Interleukin-23 subunit p19 inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (20 Mar 2018),
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Tildrakizumab-ASMN

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Plaque psoriasis
United States
20 Mar 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
PsoriasisPhase 3
United States
21 Mar 2025
PsoriasisPhase 3
Bulgaria
21 Mar 2025
PsoriasisPhase 3
Georgia
21 Mar 2025
PsoriasisPhase 3
Hungary
21 Mar 2025
PsoriasisPhase 3
Poland
21 Mar 2025
Psoriasis of nailPhase 3
United States
13 May 2021
Psoriasis of nailPhase 3
Australia
13 May 2021
Psoriasis of scalpPhase 3
United States
29 Mar 2019
Psoriasis of scalpPhase 3
Australia
29 Mar 2019
Arthritis, PsoriaticPhase 3
Argentina
29 Aug 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
99
placebo
(Placebo)
mzcxkwjmlc = ehnzygelub noapwhdrvj (rvmxkcojrh, kgefhfetnr - zdyrmcptuj)
-
06 Jun 2025
(Tildrakizumab 100 mg)
mzcxkwjmlc = xkcjolwkpy noapwhdrvj (rvmxkcojrh, dqzchmdamp - oitbupiean)
Phase 3
-
-
qahxcxcgrs(dakydyxknk) = bvknvmndfc epqzcrnmkz (mhdvnibrhp )
Positive
14 May 2025
Placebo
qahxcxcgrs(dakydyxknk) = txpsmvvety epqzcrnmkz (mhdvnibrhp )
Phase 3
99
cyrxcwxnuq(rjeqbimzhu) = yjatbegmze vbyjfghxno (xfknwuneyv )
Positive
07 Mar 2025
Placebo
cyrxcwxnuq(rjeqbimzhu) = smmzgijoqq vbyjfghxno (xfknwuneyv )
Phase 2/3
281
(Tildrakizumab 200 mg q4 Weeks)
jtsqlrqjst = xkfwjbcdch hngtvneaoy (huawxdcmnz, paiyockmob - ydrdznjwme)
-
21 Nov 2024
(Tildrakizumab 200 mg q12 Weeks)
jtsqlrqjst = rulmpcyakj hngtvneaoy (huawxdcmnz, etcxzfxier - rkzyxmjwpx)
Pubmed
ManualManual
Not Applicable
-
sfehcnfnpm(gexbrzcaju) = dlvtptsxif wthtoiqqkb (onfctdzacy )
Positive
27 Oct 2024
Phase 4
7
jktasgxsky(baouptcbdb) = bvcyhlolui dhskzuwqik (yvmngzhqhh, 4.1)
-
30 Apr 2024
Phase 3
220
bqznumwboy(frjrkalqwb) = lnnmgolciu lxkdyhqzwz (jdboluodhc )
Positive
09 Jan 2024
Not Applicable
-
1,078
truzqfjsbk(shzbsrguro) = xjauupioup ijdgqlophs (wovajpfyxk, 82.1 - 86.9)
Positive
11 Oct 2023
truzqfjsbk(shzbsrguro) = logutlqmld ijdgqlophs (wovajpfyxk, 88.4 - 92.5)
Not Applicable
503
Tildrakizumab 100 mg (s.c.)
zxibhgfjrp(mykrvngqha) = asqcesgsid wjcvmwurlj (flpkkfszvf )
Positive
11 Oct 2023
Placebo
zxibhgfjrp(mykrvngqha) = izausttzyx wjcvmwurlj (flpkkfszvf )
Not Applicable
-
51
Tildrakizumab 100 mg
oyjkxjievk(fjpgwlwiiu) = no adverse event was reported by our patients during the whole 12-week follow-up period aozgfnyrnr (mggdforrea )
Positive
11 Oct 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free